A European partner in Life Science

Our vision is to improve people's lives by being a leading, value-adding partner in Life Science

Interim Report Q3 2025
Graph

Share price

2025-11-07

Press Releases

  • Good organic growth and strong earnings performance

    Margin improvements remain the highest priority, and during the quarter, profitability was clearly strengthened in both business areas. The margin improvements are mainly driven by ongoing efficiency initiatives, a continuous shift in the product portfolio towards more advanced, as well as active pricing efforts. Organic growth in the quarter was driven by positive developments in both business areas. Our acquisitions have developed well, with strong growth, improved margins, and significantly improved cash flows. Profit for the period improved by 228 percent in the quarter.

    comments by the ceo
    Fredrik Dalborg Addlife Q3 2025 Sq
  • Quote

    Authentic company culture

    - Anand Lachmansingh, entrepreneur and founder of Bio-Connect

    From the very beginning, I was struck by AddLife’s personal approach and authentic company culture. They didn’t just see a business, they saw people, potential, and purpose.

    Stories from our subsidiaries
    Anand En Groep500
  • Quote

    Right chemistry from the start

    - Michael Hartman, entrepreneur and former co-owner of BioCat

    Every step of the process, from initial talks to signing the contract, was pragmatic, straightforward, and quick.

    Stories from our subsidiaries
    Biocat 2022

Our business areas

Medtech

MEDTECH

In the Medtech business area, the subsidiaries offer products and services in medical technology, as well as assistive equipment and digital solutions for use in home care. Medtech has two business units - Hospital and Homecare. The Medtech offering mainly focuses on publicly funded healthcare, home care and social care in Europe.

Read more
Labtech

LABTECH

The Labtech business area provides products, solutions and services in fields such as diagnostics, biomedical research and laboratory analysis. The business area consists of two business units: Biomedical and Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies in Europe.

Read more

Join the AddLife group

Do you have a Life Science company with opportunities to grow? We offer an attractive option with a decentralized business model where we combine the strength of a large enterprise with the dedication and business skills of an entrepreneur. As an AddLife subsidiary, you are responsible for your business activities within the AddLife requirements for growth, profitability and sustainable development.

Acquisitions

News from our subsidiaries

DSC 0111 BMI 2025
04 November 2025
Strong company values

Positive feedback from entrepreneurs within the AddLife family gave me the confidence to join,

Biomedica Italia
30 October 2025 | Hepro
The first ever Girl Tech Fest in Saltdal

Hepro attended the Girl Tech Fest, an inspiring event series designed to introduce young girls to the world of technology through creative and practical workshops, aiming to spark their curiosity and build confidence in STEM fields.

11 October 2025 | MBA
MBA Gijón Half Marathon

The 14th MBA Gijón Half Marathon "Villa de Jovellanos" took place, in which, continuing with our commitment to the promotion of sports practice, we participated again as collaborators and as runners.

07 October 2025 | Bio-Connect
Authentic company culture

From the very beginning, I was struck by AddLife’s personal approach and authentic company culture. They didn’t just see a business, they saw people, potential, and purpose.

See all news

Sustainability for AddLife

Sustainability is a central part of AddLife's vision to improve people's life by being a leading, value adding provider in Life Science. AddLife´s approach to sustainability is identified through three impact areas where we can have the greatest contribution to a long-term lasting business and society.

Adobestock 300716540